Long Term Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women

Official record

Identifier

NCT07735897

Recruiting locations

country

South Korea

Interventions studied

Not provided in the official record

Lead sponsor

MedicalExcellence

Target enrolment

1483 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Not yet recruiting

First posted

Jul 30, 2026

Last updated on the registry

Jul 31, 2026

Age

20 Years – 45 Years

Sex

FEMALE

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Premenopausal women with hormone receptor-positive breast cancer enrolled in the ASTRRA trial (NCT00912548).

Patients enrolled and randomized in the ASTRRA study between March 1, 2009, and July 17, 2018 (excluding screening failures).

Patients with available long-term follow-up information.

Exclusion Criteria:

* Patients with primary breast cancer meeting any of the following criteria:

Hormone receptor-negative breast cancer Unknown hormone receptor status

Patients with a history of hysterectomy or bilateral oophorectomy

Patients with breast sarcoma or squamous cell carcinoma of the breast

Patients with a history of malignancy other than breast cancer within 5 years prior to enrollment

Patients with thrombocytopenia

Patients who had previously received CMF chemotherapy (cyclophosphamide, methotrexate, and fluorouracil)

Indexed under

Ovarian Cancer